Inside This Issue - News
Federal approval of a prescription drug does not provide a shield against lawsuits from injured patients, the Supreme Court ruled earlier this month.
Walgreen Co. has chosen former Tesco USA and Wal-Mart Stores Inc. executive Bryan Pugh to run its merchandising department.
McKesson Canada has withdrawn its offer to buy Uniprix Inc. after the pharmacy owners that control Uniprix failed to tender enough shares to complete the deal.
Rite Aid Corp. has completed a $225 million loan that makes up for decreased borrowing availability under a key financing agreement renewed earlier this year.
CVS Caremark Corp. executive vice president, chief financial officer and chief administrative officer Dave Rickard says he will retire at the end of the year.
As expected, the Obama administration has made health care reform a high priority in its first proposed budget and plans to pay for it in part by reducing tax breaks for the wealthy.
The National Association of Chain Drug Stores has unveiled plans for what it calls a “multimeeting, multimedia” program to deliver timely and actionable information to NACDS members and participants in the association’s meetings.
The choice of Kansas Gov. Kathleen Sebelius as nominee for secretary of health and human services won praise from pharmacy groups that believe she will effectively support President Barack Obama’s initiatives for health care reform.
Discount Drug Mart is a survivor. At a time when most other regional drug chains have long since been swallowed up by national players, the company is celebrating its 40th anniversary as a northern Ohio retailer.
CVS Caremark Corp. has launched “Pack Your Bag,” an educational outreach program aimed at the millions of older adults who run the risk of drug interactions because they must take multiple medications to manage or treat one or more chronic health conditions.
Achievable, inevitable, imperative. Those three words, insists Generic Pharmaceutical Association (GPhA) president and chief executive officer Kathleen Jaeger, describe the industry’s assessment of the need for the Food and Drug Administration to establish a scientific and legal pathway for biogenerics.